CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations.
Ontology highlight
ABSTRACT: Combinations of metabolic blockers (incl. fenofibrate) with chemotherapeutic drugs interfere with the drug-resistance of prostate cancer cells. However, their effect on cancer stem cells-dependent microevolution of prostate cancer malignancy remains unaddressed. Here, we hypothesize that the combined docetaxel/fenofibrate treatment prompts the selective expansion of cancer stem cells that affects the microevolution of their progenies. Accordingly, we adapted a combined in vitro/in vivo approach to identify biological and therapeutic consequences of this process. Minute subpopulations of docetaxel-resistant CD133high and/or CD44high cancer stem cell-like (SCL) cells were found in prostate cancer DU145 and PC3 cell populations. When pretreated with docetaxel, they readily differentiated into
SUBMITTER: Wrobel T
PROVIDER: S-EPMC7756969 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA